PIK3CG and thymoma: Likewise, a clinical trial using the pan-PI3K inhibitor buparlisib demonstrated modest activity in B2 and B3 thymomas but was marred by the necessity for early drug cessation in over half the patients due to skin and lung toxicity (32).